Chronic proton pump inihibitor therapy and calcium metabolism

Current Gastroenterology Reports

Volumn 14, Issue 6, 2012, Pages 473-479

  Yang, Yu Xiao ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bone metabolism; Calciumabsorption; Calciumbalance; Hypergastrinemia; Hyperparathyroidism; Osteoporosis; Parathyroid glands; PPI induced hypergastrinemia; PPIs and calcium metabolism; Proton pump inhibitors

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; ERGOCALCIFEROL; OMEPRAZOLE; PARATHYROID HORMONE; PROTON PUMP INHIBITOR;

BIOSYNTHESIS; BONE METABOLISM; BONE REMODELING; BONE STRENGTH; CALCIUM ABSORPTION; CALCIUM BALANCE; CALCIUM DEPLETION; CALCIUM METABOLISM; CALCIUM TRANSPORT; CATABOLISM; CHRONIC DRUG ADMINISTRATION; DIET SUPPLEMENTATION; DRUG ANTAGONISM; FRAGILITY FRACTURE; GASTRECTOMY; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERGASTRINEMIA; HYPERPARATHYROIDISM; INTESTINE ABSORPTION; MALABSORPTION; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HYPERPLASIA; REVIEW; STOMACH ACID SECRETION; STOMACH ULCER;

BONE AND BONES; CALCIUM; HUMANS; HYPERPARATHYROIDISM; OSTEOPOROTIC FRACTURES; PARATHYROID GLANDS; PROTON PUMP INHIBITORS;

EID: 84870534648     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-012-0290-4     Document Type: Review

References (57)

1. Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002;50:1644-50
2. Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact.[erratum appears in Arch Intern Med 1922 Mar;152(3):655]. Arch Intern Med. 1991;151:2026-32
3. Hetzel DJ. Controlled clinical trials of omeprazole in the long-Term management of reflux disease. Digestion. 1992;51:35-42
4. DeVault KR, Castell DO, American College of G, et al. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190-200
5. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database [see comments]. BMJ. 1998;317:452-6
6. Martin RM, Lim AG, Kerry SM, et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther. 1998;12:797-805
7. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine h(2) receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83
8. Yang Y-X, Lewis JD, Epstein S, et al. Long-Term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-53
9. de Vries F, Cooper A, Logan R, et al. Fracture risk in patients receiving concomitant bisphosphonate and acid-suppressive medication or bisphosphonate alone. Osteoporos Int. 2007;18:S261
10. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures.[see comment]. CMAJ Can Med Assoc J. 2008;179:319-26
11. Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372
12. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2011;170:765-71
13. Corley DA, Kubo A, Zhao W, et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139:93-101
14. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28:951-9
15. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83:251-9
16. Pouwels S, Lalmohamed A, Souverein P, et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based casecontrol study. Osteoporos Int. 2011;22:903-10
17. FDA. Drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. 2010
18. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.[-see comment]. J Clin Investig. 1999;104:439-46
19. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550-5
20. Stewart AF, Vignery A, Silverglate A, et al. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab. 1982;55:219-27
21. Brunner G, Creutzfeldt W. Omeprazole in the long-Term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol-Suppl. 1989;166:101-5. discussion 11-3
22. Brunner G, Creutzfeldt W, Harke U, et al. Therapy with omeprazole in patients with peptic ulcerations resistant to extended highdose ranitidine treatment. Digestion. 1988;39:80-90
23. Koop H, Klein M, Arnold R. Serum gastrin levels during longterm omeprazole treatment. Aliment Pharmacol Ther. 1990;4:131-8
24. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-Term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990;99:621-8
25. Lind T, Cederberg C, Forssell H, et al. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol. 1988;23:1259-66
26. Lamberts R, Creutzfeldt W, Struber HG, et al. Long-Term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis [see comments]. Gastroenterology. 1993;104:1356-70
27. Koop H, Arnold R. Long-Term maintenance treatment of reflux esophagitis with omeprazole. Prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci. 1991;36:552-7
28. Hakanson R, Sundler F. Trophic effects of gastrin. Scand J Gastroenterol-Suppl. 1991;180:130-6
29. Wang TC, Koh TJ, Varro A, et al. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Investig. 1996;98:1918-29
30. Grimelius L, Johansson H, Lundqvist G, et al. The parathyroid glands in experimentally induced hypergastrinemia in the rat. Scand J Gastroenterol. 1977;12:739-44
31. Gagnemo-Persson R, Hakanson R, Sundler F, et al. Growth of the parathyroid glands in omeprazole-Treated chickens. Scand J Gastroenterol. 1994;29:493-7
32. Gagnemo-Persson R, Samuelsson A, Hakanson R, et al. Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int. 1997;61:210-5
33. Cui GL, Syversen U, Zhao CM, et al. Long-Term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol. 2001;36:1011-5
34. Mizunashi K, Furukawa Y, Katano K, et al. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53:21-5
35. Nordin BE. Calcium and osteoporosis. Nutrition. 1997;13:664-86
36. Ensrud KE, Duong T, Cauley JA, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 2000;132:345-53
37. Nordin BE, O'Loughlin PD, Need AG, et al. Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures. Osteoporos Int. 2004;15:27-31
38. Ervin RB, Wang CY, Wright JD, et al. Dietary intake of selected minerals for the United States population: 1999-2000. Advance Data 2004:1-5
39. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol. 2004;160:339-49
40. Champagne ET. Low gastric hydrochloric acid secretion and mineral bioavailability. Adv Exp Med Biol. 1989;249:173-84
41. Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med. 1987;317:532-6
42. Recker RR. Calcium absorption and achlorhydria. N Engl J Med. 1985;313:70-3
43. Chonan O, Takahashi R, Yasui H, et al. Effect of L-lactic acid on the absorption of calcium in gastrectomized rats. J Nutr Sci Vitaminol. 1998;44:869-75
44. Chonan O, Takahashi R, Yasui H, et al. Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol. 1998;44:473-81
45. Ivanovich P, Fellows H, Rich C. The absorption of calcium carbonate. Ann Intern Med. 1967;66:917-23
46. Nilas L, Christiansen C, Christiansen J. Regulation of vitamin D and calcium metabolism after gastrectomy. Gut. 1985;26:252-7
47. Thompson J. The stomach and duodenum: Postoperative complications. Philadelphia: Saunders; 1991
48. Bo-Linn GW, Davis GR, Buddrus DJ, et al. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Investig. 1984;73:640-7
49. Heaney RP, Smith KT, Recker RR, et al. Meal effects on calcium absorption. Am J Clin Nutr. 1989;49:372-6
50. Heller HJ, Greer LG, Haynes SD, et al. Pharmacokinetic and pharmacodynamic comparison of two calcium supplements in postmenopausal women.[erratum appears in J Clin Pharmacol 2001 Jan;41(1):116]. J Clin Pharmacol. 2000;40:1237-44
51. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10:1376-80
52. Graziani G, Badalamenti S, Como G, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron. 2002;91:474-9
53. Hardy P, Sechet A, Hottelart C, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the controlof hyperphosphatemia in patients on chronic hemodialysis. Artificial Organs. 1998;22:569-73
54. O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778-81
55. Serfaty-Lacrosniere C,Wood RJ, Voytko D, et al. Hypochlorhydria from short-Term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995;14:364-8
56. Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2011;25:2786-95
57. Heaney RP. Factors influencing the measurement of bioavailability, taking calcium as a model. J Nutr. 2001;131:1344S-8S.